97290 ⎘
Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components Diabody or triabody
STABLE MULTIVALENT ANTIBODY
#302Anti-CD39 antibodies and uses thereof
#303Bak binding proteins
#304Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
#305Folate receptor 1 antibodies and immunoconjugates and uses thereof
#306Kits containing DLL3 antibody drug conjugates
#307IL22 immunoconjugates
#308MULTIVALENT FRAGMENTS OF ANTIBODY 3E10 AND METHODS OF USE THEREOF
#309Bispecific HER2 antibodies
#310Anti-DLL3 antibody drug conjugates
#311ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#312Anti-DLL3 antibody drug conjugates for treating cancer
#313Methods of making DLL3 antibody drug conjugates
#314Methods of delivering DLL3 antibody drug conjugates
#315Anti-DLL3 antibody drug conjugates
#316Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
#317Midkine antibody
#318Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens
#319Tetravalent anti-PSGL-1 antibodies and uses thereof
#320Multi-chain polypeptide-containing tri-specific binding molecules
#321Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof
#322Methods and compositions for engineering immunity
#323METHODS OF DIAGNOSING ALS
#324Ligands that potentiate the bioactivity of gonadotropins
#325Ligands that potentiate the bioactivity of gonadotropins
#326Antigens associated with endometriosis, psoriatic arthritis and psoriasis
#327BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES
#328Anti-La antibodies and their use for immunotargeting
#329Antibody fragments for detecting cancer and methods of use
#330Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses Thereof
#331Serum half-life extension using IgBD
#332Compositions and methods for treating ewing sarcoma
#333KV1.3 binding immunoglobulins
#334VEGFR2/Ang2 Compounds
#335Method of making an anti-CD40 antibody
#336Nucleic acids encoding chemokine receptor binding polypeptides
#337Bispecific antibody fragments for neurological disease proteins and methods of use
#338Method for the production of domain antibodies
#339NOVEL MULTISPECIFIC MOLECULES AND NOVEL TREATMENT METHODS BASED ON SUCH MULTISPECIFIC MOLECULES
#340ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#341Antibodies to olanzapine and use thereof
#342TRKB OR TRKC AGONIST COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC CONDITIONS
#343Antigen binding constructs to CD8
#344Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#345Compositions And Methods For Modulating And Redirecting Immune Responses
#346NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A
#347Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#348Human IL-23 antigen binding proteins
#349Anti-DLL3 antibody drug conjugates for treating cancer
#350METHOD OF TREATING CANCER
#351Anti-influenza antibody
#352Soluble MIC neutralizing monoclonal antibody for treating cancer
#353BISPECIFIC CONSTRUCTS AND THEIR USE IN THE TREATMENT OF VARIOUS DISEASES
#354Trispecific antibodies
#355Covalent diabodies and uses thereof
#356Thrombin-binding antibody molecules and uses thereof
#357Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof
#358CD37-binding molecules and immunoconjugates thereof
#359Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#360Recombinant production of mixtures of antibodies
#361Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#362Internalizing ErbB2 Antibodies
#363Anti-dog IgE monoclonal antibody, and light-chain variable region and heavy-chain variable region of anti-dog IgE monoclonal antibody
#364Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody
#365IL-13 BINDING PROTEINS AND USES THEREOF
#366TNF-ALPHA BINDING PROTEINS
#367Antibodies reactive with B7-H3 and uses thereof
#368Anti-NGF antibodies and their use
#369Neutralizing anti-influenza A antibodies and uses thereof
#370Anti-DLL3 antibody drug conjugates
#371Antibody purification method, antibody obtained therefrom, novel antibody purification method using cation exchanger, and antibody obtained therefrom
#372Anti-DLL3 antibody drug conjugates
#373Material and methods for treating or preventing HER-3 associated diseases
#374Methods for treating hematologic cancers
#375Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
#376Cytotoxic agents for conjugation to a cell binding molecule
#377Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof
#378IL4 CONJUGATED TO ANTIBODIES AGAINST EXTRACELLULAR MATRIX COMPONENTS
#379Binding agent
#380Bispecific CD33 and CD3 binding proteins
#381Antibody which specifically reacts with human integrin A6B4
#382CANCER TREATMENT USING ANTIBODIES THAT BIND CELL SURFACE GRP78
#383Pharmaceutical compositions containing sc(Fv)2
#384Covalent diabodies and uses thereof
#385Stabilized antibody compositions
#386Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#387Antibody binding sites specific for EGFRvIII
#388Antigen binding proteins capable of binding thymic stromal lymphopoietin
#389BISPECIFIC ANTIBODIES
#390Human antigen binding proteins that bind β-klotho, FGF receptors and complexes thereof
#391Modified Variable Domain Molecules And Methods For Producing And Using Same
#392Methylation and acetylation sites
#393Tumor marker, monoclonal antibodies and methods of use thereof
#394Antibodies to ticagrelor and methods of use
#395CHIMERIC FVII-XTEN MOLECULES AND USES THEREOF
#396Heterodimeric bispecific antibodies
#397Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
#398CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
#399Antigen associated with the neovasculature of tumour metastases
#400Anti-IL-4/anti-IL-13 bispecific antibody formulations
#401Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
#402Chimeric antigen receptors with an optimized hinge region
#403IDENTIFICATION AND MOLECULAR CHARACTERISATION OF PROTEINS, EXPRESSED IN THE IXODES RICINUS SALIVARY GLANDS
#404CD3 binding domains
#405Methods of treating a neoplastic disease
#406BLOOD-BRAIN-BARRIER DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#407Fibronectin III domain of IL-11Rα
#408Epitope of RSV fusion protein and antibody recognizing the same
#409Antigen binding constructs to CD8
#410Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#411Therapeutic methods using anti-CD200 antibodies
#412Bispecific heterodimeric diabodies and uses thereof
#413Bispecific CD33 and CD3 binding proteins
#414Caninized anti-NGF antibodies and their use
#415Anti-CD83 antibodies and use thereof
#416Antibody constructs for CDH19 and CD3
#417Anti-ED-A immunoconjugates for inflammatory bowel disease
#418Antibodies which bind to epithelial membrane protein 2 (EMP2)
#419DEPLETION OF IL23R EXPRESSING CELLS IN THE TREATMENT OF VARIOUS DISEASES
#420Fully human antibodies and fragments recognizing human c-Met
#421Anti-blood dendritic cell antigen 2 antibodies and uses thereof
#422Antibodies against 6-sulfo-LacNac-positive human dendritic cells, and their use
#423BIO-ORTHOGONAL DRUG ACTIVATION
#424Compounds and Methods for Modulating an Immune Response
#425COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#426CLUSTER OF DIFFERENTIATION 36 (CD36) AS A THERAPEUTIC TARGET FOR HIV INFECTION
#427High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
#428Internalizing ErbB2 antibodies
#429Predictive marker for topoisomerase I inhibitors
#430ANTIGEN-BINDING MOLECULE AND USES THEREOF
#431Inhibitors of the Epidermal Growth Factor Receptor- Heat Shock Protein 90 Binding Interaction
#432Amyloid-beta binding proteins
#433ANTICOAGULANT ANTIDOTES
#434Engineered antibody-interferon fusion molecules for treatment of autoimmune diseases
#435TUMOR SPECIFIC ANTIBODY
#436ENGINEERED ANTIBODY FRAGMENTS FOR TARGETING AND IMAGING CD8 EXPRESSION IN VIVO
#437LH-TYPE BISPECIFIC ANTIBODY
#438Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis and Metastatis
#439Deimmunized serum-binding domains and their use in extending serum half-life
#440Compositions and methods for treating fatty tissue buildup
#441DNA ENCODING AN ANTI-SYSTEM ASC AMINO ACID TRANSPORTER 2 (ASCT2) ANTIBODY
#442AXL ANTIBODIES
#443Antibody that binds murine wise protein
#444Antibody against transporter and use thereof
#445Antigen binding constructs to CD3
#446Monovalent, bivalent and trivalent anti human respiratory syncytial virus (hRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
#447Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
#448IL-17 antagonist antibodies
#449MODIFIED ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
#450Pseudomonas aeruginosa PCRV binding single variable domain antibodies
#451Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors
#452Removal of tumor cells from intraoperative autologous blood salvage
#453Anti-bFGF humanized double-stranded antibody with stable disulfide bond, preparation method and application thereof
#454Bispecific antibody fragments for neurological disease proteins and methods of use
#455Dual specific binding proteins directed against IL-1 and/or IL-17
#456Immuno imaging agent for use with antibody-drug conjugate therapy
#457Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
#458Immuno imaging agent for use with antibody-drug conjugate therapy
#459Single chain multivalent binding protein compositions and methods
#460Tumor-specific recognition molecules
#461Methods of treatment using chemokine receptor binding polypeptides
#462Material and methods for treating or preventing HER-3 associated diseases
#463Internalizing erbB2 antibodies
#464Anti-NGF antibodies and their use
#465Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
#466Fragment of humanized anti-EGFR antibody substituted-lysine variable fragment and use thereof
#467Pulmonary administration of immunoglobulin single variable domains and constructs thereof
#468Highly-functional mutant of humanized anti-EGFR antibody variable region
#469Human CD3-specific antibody with immunosuppressive properties
#470STABLE MULTIPLE ANTIGEN-BINDING ANTIBODY
#471Bispecific antigen binding molecules
#472Multivalent Antibodies
#473Antigen associated with the neovasculature of tumour metastases
#474COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#475Human IL-23 antigen binding proteins
#476ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#477Podocalyxin-like-protein-1 binding antibody molecule
#478Antibodies reactive with B7-H3 and uses thereof
#479Covalent disulfide-linked diabodies and uses thereof
#480CD37-binding molecules and immunoconjugates thereof
#481MULTISPECIFIC MODULAR ANTIBODY
#482Anti-CD33 antibodies and use thereof for immunotargeting in treating CD33-associated illnesses
#483Dual Variable Region Antibody-Like Binding Proteins Having Cross-Over Binding Region Orientation
#484STABILIZED SINGLE DOMAIN ANTIBODIES
#485Antigens Associated with Inflammatory Bowel Disease Including Ulcerative Colitis
#486CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#487ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I
#488Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen as diagnostic and therapeutic tools for prostate cancer
#489TNF-α binding proteins
#490Modified Variable Domain Molecules And Methods For Producing And Using Same
#491SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#492Antigen binding proteins capable of binding thymic stromal lymphopoietin
#493Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
#494Therapeutic using a bispecific antibody
#495Chemokine receptor binding polypeptides
#496Immuno-conjugates and methods for producing them
#497Immuno-conjugates and methods for producing them
#498Method for the production of domain antibodies
#499Tumor-specific recognition molecules
#500Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections
#501USE OF TRIFUNCTIONAL BISPECIFIC ANTIBODIES FOR THE TREATMENT OF TUMORS ASSOCIATED WITH THE CD133+/EPCAM+ CANCER STEM CELLS
#502LH-type bispecific antibody
#503Dual variable domain immunoglobulins and uses thereof
#504Methods of diagnosing ALS
#505Compounds and Methods for Modulating an Immune Response
#506Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds
#507METHODS FOR PRODUCING MIXTURES OF ANTIBODIES
#508Compositions and methods for treating kidney disease
#509Folate receptor 1 antibodies and immunoconjugates and uses thereof
#510Methods of treating TSLP-related inflammatory disorders
#511Anti-NGF antibodies for the treatment of various disorders
#512Amyloid-beta binding proteins
#513Antigens associated with endometriosis, psoriatic arthritis and psoriasis
#514Material and methods for treating or preventing HER-3 associated diseases
#515Internalizing ErbB2 antibodies
#516Antigen-Binding Molecule And Uses Thereof
#517SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#518METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR
#519STABILIZED SINGLE DOMAIN ANTIBODIES
#520Recombinant production of mixtures of antibodies
#521Antibodies against cancer target block tumor growth, angiogenesis and metastatis
#522Antibodies that bind ALS specific epitopes and methods of making
#523Human antigen binding proteins that bind β-Klotho, FGF receptors and complexes thereof
#524Detection of pathogenic abeta using an epitope protection assay
#525NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING AND USES THEREOF
#526NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTASIS
#527Stable multivalent antibody
#528Anti-Mpl antibodies
#529SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST TUMOR NECROSIS FACTOR-ALPHA AND USES THEREFOR
#530Predictive marker for topoisomerase I inhibitors
#531Transmission using nested OFDMA
#532High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
#533COMPOSITIONS AND METHODS FOR IMPROVING PRODUCTION OF RECOMBINANT POLYPEPTIDES
#534Multispecific antibodies comprising full length antibodies and single chain fab fragments
#535Engineered antibody-stress protein fusions
#536ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS
#537Antigen associated with the neovasculature of tumour metastases
#538Anti-CD40 antibodies
#539Ligand
#540AMINO ACID SEQUENCES THAT BIND TO A DESIRED MOLECULE IN A CONDITIONAL MANNER
#541Anti-system ASC amino acid transporter 2 (ASCT2) antibody
#542CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#543Covalent diabodies and uses thereof
#544CROSS-SPECIES-SPECIFIC BINDING DOMAIN
#545Remedy For Chemotherapy-Resistant Cancer Containing HLA Class I-Recognizing Antibody as the Active Ingredient and Use of the Same
#546POLYPEPTIDE CONSTRUCTS FOR SUBLINGUAL ADMINISTRATION
#547Eliminating unreachable subscribers in voice-over-ip networks
#548Polypeptide constructs including VHH directed against EGFR for intracellular delivery
#549Compositions and methods for treating kidney disease
#550Bi-specific monoclonal antibody (specific for both CD3 and CD11B) therapeutic drug
#551POLYPEPTIDE CONSTRUCTS FOR TOPICAL ADMINISTRATION
#552POLYPEPTIDE CONSTRUCTS FOR RECTAL AND/OR VAGINAL ADMINISTRATION
#553Single-chain Multiple Antigen-binding Molecule, Its Preparation and Use
#554POLYPEPTIDE CONSTRUCTS FOR NASAL ADMINISTRATION
#555Dual variable domain immunoglobulins and uses thereof
#556Structural isomers of sc(Fv)2
#557Recombinant production of mixtures of antibodies
#558BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY
#559Stabilized single domain antibodies
#560Antigen binding proteins capable of binding thymic stromal lymphopoietin
#561METHODS OF TREATING AND PREVENTING ACUTE MYOCARDIAL INFARCTION
#562Pharmaceutical compositions containing sc(Fv)2
#563High functional bispecific antibody
#564Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses
#565Reagents and Methods for the Detection of Transmissible Spongiform Encephalopathy
#566BINDING PROTEIN MOLECULE
#567COMPOSITIONS THAT BIND MULTIPLE EPITOPES OF IGF-1R
#568Gene Engineering Recombinant Anti-CEA, Anti-CD3, And Anti-CD28 Single-Chain Tri-Specific Antibody
#569Stabilizer for protein preparation comprising meglumine and use thereof
#570Methods of selecting internalizing antibodies
#571TARGETED LIGANDS
#572ALS-specific peptide composition
#573Compositions comprising modified biologically active polypeptides
#574Substance that specifically recognizes PD-1
#575Engineered antibody-stress protein fusions
#576Covalent diabodies and uses thereof
#577Recombinant antibodies against CD55 and CD59 and uses thereof
#578Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
#579Bispecific antibodies that bind to vegf receptors
#580Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#581Cell Death-Inducing Agents
#582Recombinant antibodies for the detection and neutralization of anthrax toxin
#583Bispecific molecules cross-linking ITIM and ITAM for therapy
#584Modified Antibodies Recognizing Receptor Trimers or Higher Multimers
#585Trimeric collagen scaffold antibodies
#586Nucleic acids encoding polyvalent protein complexes
#587HIGH AVIDITY POLYVALENT AND POLYSPECIFIC REAGENTS
#588ANTIBODY COMBINATION USEFUL FOR TUMOR THERAPY
#589Internalizing ErbB2 antibodies
#590Humanized anti-CEA T84.66 antibody and uses thereof
#591Method for the treatment of automimmune diseases comprising administering rapamycin and IL-10
#592Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
#593Compositions and methods for treating kidney disease
#594CD44E tumor specific antibody
#595Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
#596Diabody which specifically binds surface antigen I/II and methods of use thereof
#597Therapeutic using a bispecific antibody
#598Antibody fragments specific for human carcinoembryonic antigen (CEA)
#599Stabilized single domain antibodies
#600Protein nmb0928 and use thereof in pharmaceutical formulations